Answer
CARVYKTI (ciltacabtagene autoleucel) is not recommended during pregnancy or for women of childbearing potential not using contraception; there are no available pregnancy-use data, pregnant women should be advised of possible foetal risks, and pregnancy after treatment should be discussed with the treating physician.
Sources for this answer
- CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked